XOMA Royalty (XOMA) Amortization of Deferred Charges (2011 - 2026)
XOMA Royalty (XOMA) reported Amortization of Deferred Charges of $332000.0 for Q1 2026, down 22.25% on a YoY basis from $427000.0 in Q1 2025, and up 33.33% sequentially from $249000.0 in Q4 2025.
XOMA Royalty (XOMA) Amortization of Deferred Charges (2011 - 2026) Analysis & Trends
XOMA Royalty (XOMA) has 14 years of Amortization of Deferred Charges data on file, last reported at $332000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortization of Deferred Charges fell 22.25% year-over-year to $332000.0; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (down 9.59% YoY), and the FY2025 full-year result was $1.4 million, up 2.59% from the prior year.
- Amortization of Deferred Charges climbed to $332000.0 in Q1 2026, from $249000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $427000.0 in Q1 2025 to a low of $249000.0 in Q4 2025.
- A 3-year average of $335000.0 and a median of $327000.0 in 2025 frame the typical range for Amortization of Deferred Charges.
- Peak annual rise in Amortization of Deferred Charges reached 39.54% in 2025, while the deepest fall reached 29.66% in 2025.
- Tracing XOMA's Amortization of Deferred Charges over 3 years: stood at $354000.0 in 2024, then slipped by 29.66% to $249000.0 in 2025, then jumped by 33.33% to $332000.0 in 2026.
- Business Quant data shows XOMA's Amortization of Deferred Charges at $332000.0 in Q1 2026, $249000.0 in Q4 2025, and $322000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 332,000.00 |
| Mar 31, 2026 | 332,000.00 |
| Dec 31, 2025 | 249,000.00 |
| Dec 31, 2025 | 249,000.00 |
| Jun 30, 2025 | 322,000.00 |
| Jun 30, 2025 | 322,000.00 |
| Mar 31, 2025 | 427,000.00 |
| Mar 31, 2025 | 427,000.00 |
| Dec 31, 2024 | 354,000.00 |
| Dec 31, 2024 | 354,000.00 |
| Sep 30, 2024 | 408,000.00 |
| Sep 30, 2024 | 408,000.00 |
| Jun 30, 2024 | 282,000.00 |
| Jun 30, 2024 | 282,000.00 |
| Mar 31, 2024 | 306,000.00 |
| Mar 31, 2024 | 306,000.00 |
| Jun 30, 2021 | 73,000.00 |
| Jun 30, 2021 | 73,000.00 |
| Mar 31, 2021 | 127,000.00 |
| Mar 31, 2021 | 127,000.00 |